Application of tauroursodeoxycholate in preparation of medicine for treating kidney injury caused by COL4A3 gene mutation
By using taurum deoxycholate to improve renal damage caused by COL4A3 mutation, the inadequacy of treatment for renal injury caused by COL4A3 gene mutation was solved, and the progression of renal lesions and inflammation was significantly improved, providing a safe and effective treatment plan for pediatric patients.
Patent Information
- Application Number
- CN202411047921.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-25
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-08
AI Technical Summary
There is currently a lack of effective treatments to deal with renal damage caused by COL4A3 gene mutations, especially hereditary chronic kidney disease. The existing therapeutic drugs are limited in effect and lack safe and effective early treatment options for childhood patients.
TUDCA is used as the active ingredient drug to improve the abnormal folding and secretion of type IV collagen in podocytes, inhibit the endoplasmic reticulum stress response, reduce the progress of renal inflammation, and significantly improve glomerulus The open capillary loop and the fusion of podocyte foot processes delay the progression of nephropathy.
TUDCA significantly improved renal lesions in COL4A3 mutant mice, reduced urinary albumin/urinary creatinine ratio and serum creatinine levels, delayed the progression of nephropathy, and proved its safety and effectiveness in childhood patients, becoming a COL4A3 mutation-related nephropathy effective early treatment drugs.
Smart Images

Figure CN118903151A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of pharmaceutical technology, in particular to the use of tauroursodeoxycholate in the preparation of a drug for treating kidney damage caused by COL4A3 gene mutation. Background Art
[0002] Chronic kidney disease (CKD) is a major health problem worldwide, causing great social and economic burdens. Genetic factors are an important cause of CKD. Previous literature reports that about 25% of CKD patients have a positive family history, but there is still a lack of mechanism research and treatment drugs.
[0003] Collagen Type IV (COL4As) mutations have been identified as the most common cause of hereditary CKD and are an important cause of Alport syndrome (AS), thin basement membrane nephropathy (TBMN), and hereditary focal segmental sclerosis nephropathy (FSGS). Such patients may develop the disease in childhood, and some patients may progress to end-stage renal disease (ESRD) in middle age. Although clinical experience suggests that anti-angiotensin system inhibitors (RAS inhibitors) can reduce urine protein and delay renal function decline in such patients, the effect is limited. Therefore, there is currently no effective method for treating diseases related to COL4As mutations. Therefore, it is of great clinical significance to deeply explore the intervention mechanism of COL4A3 gene mutations and explore new therapeutic targets.
[0004] COL4As are composed of a 7s domain, a collagen domain with Gly-XY repeats, and a non-collagenous domain (NC1). Type IV collagen α3α4α5 (encoded by COL4A3 / 4 / 5 genes) is synthesized in the endoplasmic reticulum of podocytes, and forms a heterotrimer through cross-linking of the NC1 region of three peptide chains, which is then secreted into the extracellular matrix to construct the glomerular basement membrane (GBM) to maintain the integrity of the glomerular filtration barrier function. Our previous studies have confirmed that mutated type IV collagen molecules cannot be properly assembled into a triple helical structure, and abnormal folding and accumulation occur in the endoplasmic reticulum, leading to endoplasmic reticulum stress lesions, further activating the TLR / Myd88 / P38 MAPK pathway, promoting apoptosis, leading to kidney damage, and stimulating the secretion of inflammatory mediators to mediate glomerular and renal interstitial lesions. The pathogenic mechanism of kidney damage caused by COL4A3 mutations has been clarified. The mutant mice gradually developed uneven thickness of the glomerular basement membrane, poor opening of the glomerular capillary loops, and fusion of the foot processes of the glomerular podocytes. The mice also had elevated blood creatinine (Scr) levels and increased urine protein, which was consistent with the progression of the human disease (glomerular basement membrane lesions, podocyte shedding, foot process fusion, and clinical manifestations of progressive increase in blood creatinine, proteinuria, and microscopic hematuria).
[0005] Tauroursodeoxycholic acid (TUDCA) is an effective inhibitor of endoplasmic reticulum stress. At the same time, it is also a molecular chaperone drug that can stabilize protein structure and help misfolded proteins to fold and secrete correctly. It is widely used in the treatment of cholestatic liver disease, amyotrophic lateral sclerosis, etc. It can be taken safely and for a long time, and is also applicable to pediatric patients. At present, the pharmacological mechanism of TUDCA has been comprehensively studied, proving that TUDCA can reduce endoplasmic reticulum stress, oxidative stress, inhibit cell apoptosis and reduce inflammation in ischemia-reperfusion, acute myocardial infarction, and acute and chronic models of Parkinson's disease. This suggests that TUDCA has good application prospects.
[0006] Chinese patent document CN115135323A discloses a pharmaceutical composition. Chinese patent document CN115484940A discloses an adrenaline pharmaceutical preparation for intranasal delivery. However, there is no report on the use of tauroursodeoxycholate in the preparation of a drug for treating kidney damage caused by COL4A3 gene mutation. Summary of the invention
[0007] The object of the present invention is to provide a new use of tauroursodeoxycholate (TUDCA).
[0008] The first aspect of the present invention provides the use of tauroursodeoxycholate in the preparation of a drug for treating kidney damage caused by type IV collagen (Collagen Type IV, COL4As) gene mutation.
[0009] Furthermore, the COL4A3 gene mutation kidney damage treatment drug contains tauroursodeoxycholate as the sole active ingredient or is a pharmaceutical composition containing tauroursodeoxycholate.
[0010] Furthermore, the drug for treating kidney damage caused by COL4A3 gene mutation comprises a therapeutically effective amount of tauroursodeoxycholate and pharmaceutically acceptable excipients.
[0011] Furthermore, tauroursodeoxycholate effectively improves the abnormal folding and secretion of type IV collagen in podocytes, improves the endoplasmic reticulum stress response, inhibits the subsequent progression of kidney inflammation, significantly improves the opening of glomerular capillary loops and podocyte foot process fusion, significantly reduces kidney lesions, and delays the progression of kidney disease.
[0012] The second aspect of the present invention provides the use of tauroursodeoxycholate in the preparation of a drug for treating hereditary chronic kidney disease.
[0013] Furthermore, the hereditary chronic kidney disease is hereditary chronic kidney disease caused by COL4As gene mutation.
[0014] The third aspect of the present invention provides a drug for treating kidney damage caused by COL4A3 gene mutation, wherein the active ingredient of the drug is tauroursodeoxycholate.
[0015] The advantages of the present invention are:
[0016] In view of the mechanism of action of TUDCA, the present invention applies this type of drug to the treatment of COL4A3 mutation-related nephropathy, and explores its benefit mechanism in improving podocyte damage caused by COL4A3 mutation. The present invention divides 10-week-old wild-type mice and COL4A3 mutant mice of the same age into a saline-treated wild-type mouse group, a TUDCA-treated wild-type mouse group, a saline-treated mutant mouse group, and a TUDCA-treated mutant mouse group. According to the grouping, gavage once a day for 4 months (TUDCA group is 50 mg / kg, EMD Millipore). At the same time, the present invention is further verified in a human podocyte cell line overexpressing COL4A3 mutation cultured in vitro. The results showed that compared with homozygous mutant mice, TUDCA treatment effectively improved the abnormal folding and secretion of type IV collagen in podocytes of mutant mice, improved the endoplasmic reticulum stress response, inhibited the subsequent progression of kidney inflammation, significantly improved the opening of glomerular capillary loops and podocyte foot process fusion, significantly alleviated kidney lesions, and delayed the progression of kidney disease. No developmental abnormalities were observed, confirming the safety of TUDCA and that it can be an effective early treatment for COL4A3 mutations, especially in pediatric patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 :TUDCA treatment has a protective effect on the kidneys of COL4A3 p.G799R mutant mice. Note: A) The changes in urine ACR of wild-type mice treated with normal saline, mutant mice treated with normal saline, wild-type mice treated with TUDCA, and mutant mice treated with TUDCA were detected (n=5 / group). B) The changes in blood Scr of wild-type mice treated with normal saline, mutant mice treated with normal saline, wild-type mice treated with TUDCA, and mutant mice treated with TUDCA were detected (n=5 / group). *p<0.05, **p<0.01, ****p<0.0001, ns, no statistical difference. Urinary albumin creatinine ratio, ACR, urine albumin / urine creatinine. Serum creatinine, Scr, serum creatinine.
[0018] Figure 2:Renal pathological staining to observe the protective effect of TUDCA treatment on the kidneys of COL4A3 p.G799R mutant mice. Note: A) Effect of TUDCA intervention on mouse glomerular lesions (PAS staining, x400 times, Scale Bar = 20μm. B) Effect of intervention on tubular damage (HE staining, ×400 times, Scale Bar = 20μm. C) Analysis of the effect of TUDCA intervention on the glomerular / Bowman capsule volume ratio. D) Electron microscopy evaluation of the improvement of podocyte foot process fusion in mutant mice after TUDCA treatment. ****p<0.0001, ns no statistical difference.
[0019] Figure 3 :TUDCA treatment improves ERS in mutant mouse kidneys and inhibits activation of the myd88 / P38 MAPK pathway. Note: A) Effect of TUDCA intervention on the expression level of ERS-related proteins in mouse renal cortex. B) Effect of TUDCA intervention on the expression level of myd88 and pP38MPAK proteins in mouse renal cortex. C) Immunohistochemistry showed that the expression level of pP38MPAK in the glomeruli of mutant mice was significantly reduced after TUDCA intervention (x400 times, Scale Bar = 20μm)
[0020] Figure 4 :TUDCA treatment improves renal inflammation and fibrosis in COL4A3 p.G799R mutant mice. Note: A) TUDCA treatment down-regulates the levels of fibrosis-related proteins in the renal cortex of COL4A3 p.G799R mutant mice. B) TUDCA intervention inhibits the expression of MCP-1, an inflammation-related protein in the renal cortex of mutant mice. C) TUDCA inhibits the expression levels of inflammation-related genes in the renal cortex of mutant mice. *p<0.05, **p<0.01, ***p<0.001, ns, no statistical difference. DETAILED DESCRIPTION
[0021] The specific implementation methods provided by the present invention are described in detail below in conjunction with examples.
[0022] Example:
[0023] 1. Experimental Methods
[0024] 1. Collection of Mouse Specimens
[0025] Random urine was collected from mice at 8, 16, 24, and 40 weeks of age through metabolic cages, and then stored at -80°C. Venous blood was obtained by sampling the medial canthal vein. The venous blood was allowed to stand at room temperature for 2 hours and then centrifuged at 3500rpm for 15 minutes to collect the supernatant, which was then stored at -80°C. The abdominal cavity of the mouse was opened to expose the kidneys, and the chest cavity of the mouse was opened to expose the heart of the mouse for cardiac perfusion. Both kidneys of the mouse were removed, the renal capsule was removed, and the kidney was cut in half along the long axis of the mouse kidney. Half of the kidney was placed in 4% paraformaldehyde for fixation for 24 hours, and then tissue embedding, paraffin sectioning, and PAS, H&E, Masson trichrome, and immunohistochemical staining were performed. Take about 1mm from the upper and lower poles of the mouse kidney. 3 Tissues of different sizes were stored in electron microscopy fixative and sent to the Electron Microscopy Room of the School of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine for embedding. Some tissues were embedded in OCT fixative and quickly frozen in a -80°C refrigerator. The renal cortex of the remaining renal tissues was removed to prepare for subsequent Western Blot and RT-qPCR experiments.
[0026] 2. Mouse RNA Extraction
[0027] 1) First, precool the high-speed centrifuge to 4°C.
[0028] 2) Prepare 75% ethanol (1 volume of DEPC water + 3 volumes of anhydrous ethanol of analytical grade) and place on ice.
[0029] 3) Take the mouse renal cortical tissue frozen in liquid nitrogen, add 1 ml of Trizol for every 200 mg of tissue, put 1 smallest white magnetic bead + 1 large white magnetic bead into each tube, grind the tissue with a tissue homogenizer at 60 Hz*20 s*2 times (until the homogenate is formed and no solid tissue is visible to the naked eye), and let it stand on ice for 30 min.
[0030] 4) Collect the tissue lysate into RNAse free EP tube (this step can be stored at -80℃).
[0031] 5) Add 0.2 ml of chloroform (trichloromethane), shake vigorously for 15 seconds, shake for 1 second and invert once, and let it stand at room temperature for 10 minutes.
[0032] 6) Centrifuge at 4℃*12,000rpm*15min. The tube is divided into three layers (upper RNA layer, middle DNA layer, lower protein layer). Carefully transfer about 400μl of the upper aqueous phase to another RNAse free EP tube, add 1:1 volume of isopropanol, slowly invert upside down 8 times, and leave at room temperature for 10min.
[0033] 7) Centrifuge at 4°C, 12,000 rpm, for 15 min.
[0034] 8) Pour off the supernatant gently, invert on a dust-free paper to absorb the residual liquid, add 1 ml of 75% alcohol (diluted with DEPC water), turn it upside down several times, centrifuge at 4°C*7500rpm*10min, and pour off the supernatant.
[0035] 9) Repeat once, add 1 ml of 75% alcohol (diluted with DEPC water), invert several times, centrifuge at 4°C*7500 rpm*10 min, and discard the supernatant.
[0036] 10) Centrifuge the EP tube with the liquid absorbed again at 7500rpm*1min, cover the 20μl pipette with a 10μl pipette tip, absorb the remaining liquid (avoid sucking up the precipitate), open the lid and let it dry at room temperature for 5min.
[0037] 11) Add 15-20 μl of DEPC water to each well to dissolve RNA.
[0038] 12) Measure the OD value and RNA concentration of the obtained RNA by Nanodrop, record them on the wall of the corresponding EP tube and store them at -80℃ for future use;
[0039] 3. Reverse transcription of extracted RNA into cDNA
[0040] 1) Prepare the reaction mixture on ice throughout the process
[0041] 2) The reaction system was 20 μl / well and the total RNA volume was 1 μg.
[0042] 3) The reaction system is as follows: (TAKARA, RR036A kit)
[0043]
[0044] The reaction procedure for reverse transcription of RNA into cDNA is: 37℃*15min; 85℃*5sec; 4℃*∞.
[0045] 4. Real-time fluorescence quantitative PCR (qPCR)
[0046] 1) Dilute the obtained cDNA 4 times with DEPC water.
[0047] 2) This part of the experiment was carried out using TAKARA's TB green real-time fluorescence quantitative PCR kit.
[0048] 3) Label the EP tubes according to the corresponding number of samples and the number of genes to be tested, prepare the following reaction system, mix the system well, and place it on ice.
[0049]
[0050]
[0051] 4) According to the above system, set up duplicate wells for the test samples.
[0052] 5)qPCR machine procedure:
[0053] i. Stage 1 (pre-denaturation): 95°C, 30 s;
[0054] ii. stage 2 (PCR reaction stage): 95°C, 5s; 60°C, 30s (fluorescence photography); 40 cycles in total.
[0055] iii. Stage 3 (melting curve).
[0056] 6) After the above steps are completed, the relative quantitative analysis (2-△△Ct) is used to calculate the analysis results. (△Ct = Ct value of the target gene - Ct value of the internal reference gene, △△Ct = △Ct value of the experimental group - △Ct value of the control group) (internal reference is GAPDH)
[0057] 7) Primer sequence of target gene:
[0058] Table 1. RT-qPCR target gene primer sequences
[0059]
[0060] 5. Protein extraction from cells and mouse kidney tissue
[0061] 1) Prepare total protein lysis buffer: Mix RIPAlysis with 100x protease inhibitor and 100x phosphatase inhibitor.
[0062] 2) Cell protein extraction: Add 100 μl of the mixture to each well of a six-well plate, scrape the cells evenly, and place on ice for 30 min.
[0063] 3) Renal tissue protein extraction: Weigh the renal cortex, add the corresponding volume of the mixture and two grinding magnetic beads, grind the tissue using a tissue homogenizer at 60 Hz*20 s*2 times (until the homogenate is formed and no solid tissue is visible to the naked eye), and let it stand on ice for 30 min.
[0064] 4) Centrifuge at 4°C, 12,000 rpm, for 15 min, and transfer the supernatant to a new EP tube.
[0065] 6. BCA protein assay
[0066] 1) According to the Biotech BCA Assay Kit, prepare the BCA standard to a final concentration of 0.5 mg / ml, aliquot and store at -20°C.
[0067] 2) Dilute the cell protein stock solution 10 times with PBS and dilute the kidney tissue protein stock solution 30 times. Mix thoroughly and place on ice.
[0068] 3) In a 96-well ELISA plate, add the 0.5 mg / ml concentration standard bottle in the order of 0 μl, 1 μl, 2 μl, 4 μl, 8 μl, 12 μl, 16 μl, and 20 μl to the 96-well plate (set up double wells), and then add PBS to each well to a final volume of 20 μl. Add 20 μl of the sample to be tested to the remaining wells in turn.
[0069] 4) At the same time, according to the number of samples to be measured, mix the A solution and B solution of the BCA kit in a volume ratio of 50:1. Add 200 μl to each well of the standard well and sample well, incubate at 37°C for 30 minutes, and measure the OD value between 540-595 nm.
[0070] 5) At this time, the concentrations of the standard are 0, 0.025, 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5 mg / ml per well. Draw a standard curve according to the OD value and the concentration of the standard, and calculate the measured concentration (μg / μl) and actual concentration of each sample.
[0071] 6) Add 5× loading buffer to each sample according to its volume, mix well, and heat at 100℃ for 10 min. Aliquot and store at -80℃ until use.
[0072] 7.Western blot
[0073] 1) Use a 1.5 mm glass plate to prepare SDS gel. After the glass plate is assembled, use anhydrous ethanol to check for leaks and then discard the anhydrous ethanol.
[0074] 2) According to the molecular weight of the target protein, prepare about 7.5 ml of SDS polyacrylamide gel electrophoresis separation gel of different concentrations of 6%, 7.5%, 10%, 12.5%, and 15%, add it to the glass plate, seal it with anhydrous ethanol for about 30 minutes, and wait for the gel to solidify. Pour out the anhydrous ethanol and absorb the ethanol with dust-free paper.
[0075] 3) Prepare 5% concentrated gel according to the following method, mix well and cover with separation gel, quickly insert into 15-hole or 10-hole comb, wait for 30 minutes before use.
[0076]
[0077] 4) Sample loading and electrophoresis: Prepare the electrophoresis solution according to the following formula, pour the electrophoresis solution into the electrophoresis tank, and remove the comb. Load the samples in the order of protein marker and sample protein, with 20 μg of cell protein and 40 μg of tissue protein. After 30 minutes of constant voltage electrophoresis at 80V, switch to 120V constant voltage and continue electrophoresis until bromophenol blue reaches the bottom of the gel, then stop electrophoresis.
[0078] 5) Transfer: Use a seesaw to separate the two glass plates and remove the concentrated gel. Cut a PVDF membrane, two transfer filter papers, and two transfer sponges of the same area as the separation gel. Use analytical grade methanol to fully activate the PVDF membrane, pour in the pre-cooled transfer solution, and perform western blot transfer in the order of the black side of the transfer clip, transfer sponge, transfer filter paper, gel, PVDF membrane, transfer filter paper, transfer sponge, and white side of the transfer clip (prevent bubbles from forming during the process). (Transfer conditions: constant current 300mA transfer 1KD / min, ice bath.)
[0079]
[0080] 6) Preparation of 1x TBST solution: Dissolve 25 ml of 20x TBS in 500 ml of dd water, add 0.5 ml of Tween-20, and mix thoroughly.
[0081] 7) Blocking: Block with 5% BSA (5 g BSA + 100 ml 1X TBST solution), mix thoroughly, and block the transferred membrane at room temperature for 1 hour.
[0082] 8) Cut the membrane to the appropriate size according to the position indicated by the marker. Wash the membrane with 1x TBST for 5 minutes*3 times.
[0083] 9) Primary antibody incubation: dilute the primary antibody with commercial antibody diluent or 5% BSA solution according to the recommended ratio in the antibody manual. Incubate the primary antibody at 4°C overnight.
[0084] 10) Wash the membrane with 1x TBST for 5 min*3 times.
[0085] 11) Secondary antibody incubation: According to the species of the primary antibody, incubate the PVDF membrane with Goat anti-Rabbit secondary antibody or Goat anti-Mouse secondary antibody (secondary antibody dilution ratio is 1:5000) at room temperature for 1 hour.
[0086] 12) Wash the membrane with 1x TBST for 5 min*3 times.
[0087] 13) Mix ECL solution A and solution B in a ratio of 1:1; immediately cover the membrane in the ECL solution for 1 min, illuminate with a chemiluminescence instrument, and save the image.
[0088] 8. Detection of mouse blood Scr and urine ACR
[0089] 1) Mouse blood Scr detection: Mouse blood Scr was detected according to the standard procedure of Crystal CC kit.
[0090] 2) Mouse urine Cr detection: According to the standard process of the Exocell kit, the absorbance value level in the mouse random urine was detected. The appropriate dilution multiple of the urine sample was obtained in the preliminary experiment. The absorbance of each sample was calculated according to the formula: A delta =A alkaline picrate -A alkaline picrate+acid . Use the A of each standard delta The least squares regression equation was determined based on the ratio of creatinine concentration to creatinine concentration, and the urinary Cr value of each mouse was calculated by this equation, which was then multiplied by the dilution factor to obtain the actual value of urinary Cr.
[0091] 3) Mouse urine alb detection: According to the standard procedure of the Exocell kit, the absorbance value of urine alb in random mouse urine was detected. The appropriate dilution multiple of the urine sample was obtained in the preliminary experiment. The concentration and absorbance of the standard were analyzed by semi-logarithmic analysis to obtain the following equation log 10 MSA=m A 450 + b, the calculated value of urine ALB for each mouse was calculated by this equation and multiplied by the dilution factor to obtain the actual value of urine ALB.
[0092] 4) Urine ACR value = urine alb / urine Cr (convert the units).
[0093] 9. Paraffin Embedding of Mouse Tissue
[0094] 1) The kidneys were fixed in 4% paraformaldehyde for 24 hours and then rinsed under running water for 2 hours.
[0095] 2) Dehydration: The tissue was immersed in 70% ethanol overnight, then immersed in two 80% ethanol concentrations for 30 min, then immersed in two 95% ethanol concentrations for 30 min, and finally immersed in 100% anhydrous ethanol for 30 min.
[0096] 3) Transparency: Immerse in xylene twice, for 30 min each.
[0097] 4) Wax immersion: In a 60°C oven, the kidney tissue was immersed in two melted liquid paraffins in sequence, each for 2 hours.
[0098] 5) Embedding and sectioning: trim the section of the solidified paraffin block containing the tissue, cut it into 3 μm thick sections, spread the sections in a 40°C water bath, and bake the sections on anti-shedding slides at 60°C for 6 hours before use.
[0099] 10. H&E staining
[0100] 1) Dewaxing: Place 3 μm mouse kidney tissue paraffin sections in a 70°C oven for 1 hour. Then dewax the sections in xylene I and xylene II for 20 minutes each.
[0101] 2) Hydration: Place the sections in anhydrous ethanol I and anhydrous ethanol II for 5 min each, then place them in 95% ethanol and 80% ethanol for 10 min each, and then rinse them in tap water for 10 min.
[0102] 3) Staining: Slices were stained with Harris hematoxylin for 5 minutes, then rinsed with running water for 5 minutes. Then, the slices were soaked in 1% hydrochloric acid alcohol (absolute ethanol: distilled water: concentrated hydrochloric acid volume ratio = 70:30:1), rinsed with tap water for 10 minutes to turn blue, washed once with double distilled water, and quickly soaked in 95% ethanol.
[0103] 4) Soak the sections in eosin solution for 30 seconds, 95% ethanol I and 95% ethanol II for 1 minute each, then soak in anhydrous ethanol I and anhydrous ethanol II for 2 minutes each. Soak in fresh xylene I and xylene II for 2 minutes each, and drain slightly. After sealing with neutral resin (fresh xylene diluted appropriately), observe under a microscope.
[0104] 11.PAS staining
[0105] 1) Dewax and hydrate 3 μm tissue sections.
[0106] 2) Staining: Soak the slices in 1% periodic acid solution for 15 minutes, wash in dd water 3 times * 5 minutes. Stain the slices in Schiff's stain for 10 minutes, rinse in running water for 5 minutes, and the tissue will turn pink under the naked eye.
[0107] 3) Stain the nucleus with hematoxylin for 1 min and rinse with running water for 5 min.
[0108] 4) Digest with 1% hydrochloric acid and alcohol for about 5 seconds and rinse with running water for 5 minutes.
[0109] 5) Soak in 95% ethanol I and 95% ethanol II for 1 min each, then soak in anhydrous ethanol I and anhydrous ethanol II for 2 min each. Soak in fresh xylene I and xylene II for 2 min each, drain slightly. Seal the slide with neutral resin (appropriately diluted with fresh xylene) and observe under a microscope.
[0110] 12. Immunohistochemistry of Mouse Paraffin Sections
[0111] 1) Paraffin tissue sections 3 μm.
[0112] 2) Dewaxing and hydration: bake the slides at 70℃ for 1h; dewax with xylene for 45min*2 times; hydrate with gradient alcohol: 100%*1 time, 90%*1 time, 80%*1 time, 70%*1 time, 5min each time; wash with dd water 3 times*5min.
[0113] 3) Antigen retrieval: Place the slide in 10 mmol / L pH 6.0 citrate buffer, heat in boiling water for 20 min, open the lid and cool to room temperature; PBS 3 times * 5 min.
[0114] 4) Block endogenous peroxidase: wipe off the water droplets, add 3% hydrogen peroxide, and protect from light for 15-30 minutes; wash with PBS 3 times * 5 minutes.
[0115] 5) Circle tissue and seal: circle the tissue with a brush; incubate with 1% BSA+PBS or non-immune goat serum at room temperature for 1 hour.
[0116] 6) Incubate with primary antibody: shake off the blocking serum, add primary antibody diluted with 1% BSA (pP38 antibody concentration 1:400), incubate overnight at 4°C (add a small amount of water in the wet box to prevent antibody evaporation); wash 3 times with PBS * 5 minutes.
[0117] 7) Incubate with secondary antibody: After discarding PBS, add HRP-labeled secondary antibody of the same species as the primary antibody (diluted at 1:500) to the circle, cover the tissue with secondary antibody, and incubate at room temperature for 30 minutes. Wash with PBS 3 times for 5 minutes.
[0118] 8) DAB color development: wipe off the water droplets; mix DAB A solution and B solution at a concentration of 1:1; control the color development time under a microscope. When the color turns brown, stop color development and rinse under running water for 15 minutes.
[0119] 9) Staining cell nuclei: wipe off water droplets, counterstain with Harris hematoxylin for about 1 minute, differentiate with 1% hydrochloric acid alcohol for a few seconds, rinse with tap water, turn blue with ammonia water, and rinse with running water away from the tissue for 15 minutes.
[0120] 10) Gradient alcohol dehydration and transparency: 70%, 80%, 90%, 100% alcohol gradient dehydration, pure xylene transparency. After slightly drying, seal the slide with neutral gum.
[0121] 2. Experimental Results
[0122] 1. The endoplasmic reticulum stress inhibitor TUDCA significantly alleviates the progression of renal lesions in COL4A3 mutant mice
[0123] We first dissolved 50 mg / kg TUDCA (EMD Millipore) in saline for later use. Ten-week-old wild-type mice and mutant mice of the same age were divided into saline-treated wild-type mice group, TUDCA-treated wild-type mice group, saline-treated mutant mice group, and TUDCA-treated mutant mice group. According to the grouping, the mice were given TUDCA and the same volume of saline treatment, respectively, by gavage once a day for 4 months. In order to evaluate the protective effect of molecular chaperone TUDCA on renal injury in mutant mice, the differences in urine ACR and blood Scr in the four groups of mice were compared. The results showed that the urine ACR of wild-type mice treated with saline was 19 mg / g and the blood Scr was 9 μmol / L, and the urine ACR of wild-type mice treated with TUDCA was 20 mg / g and the blood Scr was 7.6 μmol / L. Compared with wild-type mice treated with saline, there was no significant change in the blood Scr and urine ACR of wild-type mice treated with TUDCA. Compared with homozygous mutant mice, the serum Scr and urine ACR of mutant mice treated with TUDCA were significantly reduced. The urine ACR of mutant mice treated with saline was 64 mg / g and the serum Scr was 39 μmol / L. The urine ACR of mutant mice treated with TUDCA was 42 mg / g and the serum Scr was 26 μmol / L. Figure 1 ).
[0124] 2. TUDCA treatment improves renal lesions
[0125] PAS staining, H&E staining, and electron microscopy were used to examine the renal pathology of the four groups of mice. The results of PAS staining showed that the ratio of glomerular volume to Bowman's capsule volume in mutant mice was significantly reduced compared with that in wild-type control mice, and the glomerular capillary loops of mutant mice were not well opened. After TUDCA treatment, the ratio of glomerular volume to Bowman's capsule volume in mutant mice was significantly improved, indicating that the glomerular capacity of mutant mice was significantly improved after TUDCA treatment ( Figure 2 A). At the same time, we observed through H&E staining that the mutant mice had obvious vacuolar degeneration of renal tubular epithelial cells. We further observed the effect of TUDCA on the renal tubular lesions of mutant mice. The results showed that after TUDCA treatment, no significant improvement in the renal tubular vacuolar degeneration of mutant mice was observed ( Figure 2 B). Electron microscopy showed that the foot processes of mutant mice were significantly fused, and the fusion of podocyte foot processes of mutant mice was significantly improved after TUDCA treatment ( Figure 2 C, 2D). The above results suggest that TUDCA can alleviate renal damage caused by COL4A3 mutant mice.
[0126] 3. TUDCA treatment inhibits ERS and TLR / Myd88 / p38 MAPK pathways in mutant mouse kidneys
[0127] To further explore the molecular mechanism of TUDCA's protection of mutant mice's kidneys, we divided the mice into three groups: wild-type mice treated with normal saline, mutant mice treated with normal saline, and mutant mice treated with TUDCA. The renal cortex of the three groups of mice was taken for western blot and immunohistochemistry. The results showed that compared with the mutant mice treated with normal saline, the ERS level in the renal cortex of the mutant mice treated with TUDCA was significantly improved (the expression of PERK and CHOP proteins decreased), and the myd88 and pP38MAPK in the renal cortex of the mice were significantly decreased ( Figure 3 A and Figure 3 C). IHC staining of pP38MAPK protein in kidney tissue sections of mutant mice further confirmed that the pP38MAPK level in the glomeruli of the mutant group after TUDCA treatment was significantly decreased compared with the homozygous point mutation group treated with normal saline ( Figure 3 B).
[0128] 4. TUDCA treatment improves renal inflammation and fibrosis
[0129] The levels of renal fibrosis marker proteins FN, vimentin, and α-SMA in the mutant mice treated with TUDCA were significantly lower than those in the mutant mice treated with saline ( Figure 4 A). We detected the mRNA levels of inflammatory factors in the renal cortex of mice and found that compared with wild-type mice, the Myd88-p38 MAPK downstream regulatory genes IL1β, TGFβ1, IL-6, CCL5, and MCP-1 in the kidneys of mutant mice were significantly increased. After TUDCA treatment, the levels of inflammatory-related genes IL1b, TGFB1, IL6, TNFα, and CCL5 in mice were significantly decreased ( Figure 4 C). At the same time, we detected the inflammatory pathway protein MCP1. The results showed that compared with wild-type mice, the MCP1 protein in the kidneys of mutant mice was increased, and the level of the above protein in the kidneys of mutant mice was reduced after TDCA treatment ( Figure 4 B). The above results demonstrate the potential therapeutic effect of TUDCA on mutant mice.
[0130] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.
Claims
1. Application of tauroursodeoxycholate in the preparation of therapeutic drugs for kidney damage caused by COL4A3 gene mutation.
2. The use of tauroursodeoxycholate according to claim 1 in the preparation of a drug for treating kidney damage caused by COL4A3 gene mutation, characterized in that: The COL4A3 gene mutation kidney damage treatment drug uses tauroursodeoxycholate as the sole active ingredient or is a pharmaceutical composition containing tauroursodeoxycholate.
3. The use of tauroursodeoxycholate according to claim 1 in the preparation of a drug for treating kidney damage caused by COL4A3 gene mutation, characterized in that: The drug for treating kidney damage caused by COL4A3 gene mutation comprises a therapeutically effective amount of tauroursodeoxycholate and pharmaceutically acceptable excipients.
4. The use of tauroursodeoxycholate according to claim 1 in the preparation of a drug for treating kidney damage caused by COL4A3 gene mutation, characterized in that: The use of tauroursodeoxycholate in the preparation of drugs for improving the abnormal folding and secretion of type IV collagen in podocytes, improving the endoplasmic reticulum stress response, and inhibiting the subsequent progression of kidney inflammation.
5. The use of tauroursodeoxycholate according to claim 1 in the preparation of a drug for treating kidney damage caused by COL4A3 gene mutation, characterized in that: The application of tauroursodeoxycholate in the preparation of drugs for improving the opening of glomerular capillary loops and podocyte foot process fusion, significantly alleviating kidney lesions, and delaying the progression of kidney disease.
6. Application of tauroursodeoxycholate in the preparation of drugs for the treatment of hereditary chronic kidney disease.
7. The use of tauroursodeoxycholate according to claim 6 in the preparation of a drug for treating hereditary chronic kidney disease, characterized in that: The hereditary chronic kidney disease is hereditary chronic kidney disease caused by COL4As gene mutation.
8. A drug for treating kidney damage caused by COL4A3 gene mutation, characterized in that: The active ingredient of the medicine is tauroursodeoxycholate.
